Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Escherichia coli F4 fimbriae, historically known as K88, are filamentous surface appendages found on enterotoxigenic Escherichia coli (ETEC) strains that are a primary cause of diarrhea in neonatal and weaned piglets [Merck Veterinary Manual]. These fimbriae are complex protein structures composed of multiple subunits, with the FaeG protein serving as the major subunit and primary adhesin responsible for recognizing specific carbohydrate moieties on porcine intestinal receptors [UniProt: P02971]. By facilitating stable attachment to the small intestinal epithelium, F4 fimbriae enable ETEC to colonize the gut and deliver enterotoxins that disrupt electrolyte balance and cause fluid loss [PMID: 15505000]. Given their essential role in the early stages of infection, F4 fimbriae are key targets for veterinary vaccines, including live-attenuated and subunit formulations, as well as novel anti-adhesive strategies [PMID: 23433371]. Therapeutic interventions typically aim to elicit a robust mucosal immune response to block bacterial attachment or physically interfere with the interaction between the fimbriae and host cell receptors to prevent disease progression [PMID: 19146601].
Vaccines induce mucosal immunity (IgA) to block bacterial attachment; anti-adhesion agents and specific antibodies competitively bind to fimbriae or host receptors to prevent colonization.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli F4 fimbriae (F4).